These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21361747)

  • 1. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
    Bollard CM; Gottschalk S; Helen Huls M; Leen AM; Gee AP; Rooney CM
    Cytotherapy; 2011 May; 13(5):518-22. PubMed ID: 21361747
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
    Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
    Bollard CM; Gottschalk S; Leen AM; Weiss H; Straathof KC; Carrum G; Khalil M; Wu MF; Huls MH; Chang CC; Gresik MV; Gee AP; Brenner MK; Rooney CM; Heslop HE
    Blood; 2007 Oct; 110(8):2838-45. PubMed ID: 17609424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
    McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
    Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Epstein-Barr virus-associated lymphomas.
    Nikiforow S; Lacasce AS
    J Clin Oncol; 2014 Mar; 32(8):830-2. PubMed ID: 24493729
    [No Abstract]   [Full Text] [Related]  

  • 7. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent membrane protein-specific cytotoxic T lymphocytes: new hope for patients with natural killer/T-cell lymphoma?
    Yuan S; Su H
    J Clin Oncol; 2014 Sep; 32(25):2819-20. PubMed ID: 25049331
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBV-associated lymphomas in adults.
    Roschewski M; Wilson WH
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):75-89. PubMed ID: 22409825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
    Heslop HE; Sharma S; Rooney CM
    J Clin Oncol; 2021 Feb; 39(5):514-524. PubMed ID: 33434061
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
    Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
    Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to S. Yuan et al.
    Bollard CM; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Sep; 32(25):2820-1. PubMed ID: 25049328
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
    Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
    J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.
    Yang D; Shao Q; Sun H; Mu X; Gao Y; Jiang R; Hou J; Yao K; Chen Y; Sun B
    Clin Dev Immunol; 2011; 2011():716926. PubMed ID: 21969838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.
    Lutzky VP; Crooks P; Morrison L; Stevens N; Davis JE; Corban M; Hall D; Panizza B; Coman WB; Coman S; Moss DJ
    Clin Vaccine Immunol; 2014 Feb; 21(2):256-9. PubMed ID: 24351754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.